摘要
受体酪氨酸激酶(RTK)家族是由不同的细胞表面糖蛋白组成。这些酶参与和调节重要的过程,如细胞增殖,极性,分化,细胞与细胞的相互作用,信号,和细胞的生存。失调的RTKs将导致不同类型肿瘤的发展。据报道,在不同的癌症中有超过三十种RTK出现反常。由于其关键作用,特异性靶向与RTK是治疗恶性肿瘤的可靠方法。有针对性的细胞和分子疗法(个性化医学)被称为新疗法,它可以防止肿瘤细胞的增殖和侵袭和干扰对肿瘤生存和生长必不可少的分子。特异性单克隆抗体靶向于RTK对治疗恶性肿瘤以及自身免疫性疾病是十分有趣的。越来越多的单克隆抗体被批准表明这些治疗方法应用的增多以及越来越受到人们的关注。由于高的特异性, mAbs是靶向于在肿瘤细胞表面表达的RTKs的最有前景的物质。本文回顾了单克隆抗体靶向于oncogenic RTKs以治疗癌症的最新研究进展。
关键词: 癌症,单克隆抗体,受体酪氨酸激酶,靶向治疗。
Current Drug Targets
Title:Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Volume: 17 Issue: 14
Author(s): Mahdi Shabani and Mohammad Hojjat-Farsangi
Affiliation:
关键词: 癌症,单克隆抗体,受体酪氨酸激酶,靶向治疗。
摘要: Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins. These enzymes participate in and regulate vital processes such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling, and cell survival. Dysregulation of RTKs contributes to the development of different types of tumors. RTKs deregulation in different types of cancer has been reported for more than 30 RTKs. Due to their critical roles, the specific targeting of RTKs in malignancies is a promising approach. Targeted cellular and molecular therapies (personalized medicine) have been known as new types of therapeutics, which prevent tumor cell proliferation and invasion by interfering with molecules essential for tumor growth and survival. Specific targeting of RTKs using monoclonal antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The growing number of mAbs approved by the authorities implies on the increasing attentions and applications of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances that target RTKs expressed on the tumor cell surface. In this communication, we review the recent progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
Export Options
About this article
Cite this article as:
Mahdi Shabani and Mohammad Hojjat-Farsangi , Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy, Current Drug Targets 2016; 17 (14) . https://dx.doi.org/10.2174/1389450116666151001104133
DOI https://dx.doi.org/10.2174/1389450116666151001104133 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Multi-Modal Imaging and Cancer Therapy Using Lanthanide Oxide Nanoparticles: Current Status and Perspectives
Current Medicinal Chemistry Magnetic Nanoparticles as Both Imaging Probes and Therapeutic Agents
Current Topics in Medicinal Chemistry Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Tumour Cytochrome P450 and Drug Activation
Current Pharmaceutical Design Myogenic Differentiation of Mesenchymal Stem Cells is Induced by Striated Muscle Influences in vitro
Current Signal Transduction Therapy